Dominant Negative TGF-β Receptor Type II (TGF-βRII) Lentivirus

Description

Dominant Negative TGF- β Receptor Type II (TGF- β RII) Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. These viruses result in expression of human dominant negative TGF- β RII, missing the intracellular kinase domain (NM_003242.6; amino acid 1-191), driven by an EF1a promoter and a puromycin selection marker (Figure 1).




Figure 1. Schematic of the lenti-vector used to generate Dominant Negative TGF-8 Receptor Type II (TGF-8RII) Lentivirus.

Background

Transforming growth factor receptor beta 2 (TGFBR2), or TGF β RII, encodes the TGF β receptor serine/threonine kinase, which is a transmembrane protein that forms a heterodimeric complex with other receptor proteins and binds TGF β . The association of TGF β with TGF β RII leads to the phosphorylation of proteins, such as SMADs, involved in cell proliferation, cell cycle arrest, wound healing, and immunosuppression. Dysfunction of the TFG β signaling tends to result in cancer development and progression. In the case of solid tumors, TGF β signaling plays a role in creating a highly immunosuppressive TME (tumor microenvironment), restricting the efficacy of CAR (chimeric receptor antigen)- T cells, which have proved successful in the treatment of hematological cancers. Recently, the use of CAR-T cells armored with a dominant negative form of TGF β RII, missing the intracellular kinase domain, for the treatment of prostate cancer resulted in promising outcomes. 5 out of 13 patients did suffer cytokine release syndrome, which continues to be a concern with CAR-T applications, but on the whole the use of a dominant negative TGF β receptor to armor CAR-T cells appears to be an approach that deserves further attention in the cancer therapy field.

Application(s)

- Expression of human dominant negative TGF-βRII in cells of interest.
- Generate cell pools or stable cell lines expressing human TGF-βRII following puromycin selection.

Formulation

The lentivirus particles were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS. Virus particles can be packaged in custom formulations and produced at higher titers by special request, for an additional fee.



1

Size and Titer

Two vials (500 μ l x 2) of lentivirus at a titer $\geq 10^7$ TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.

Storage

Lentiviruses are shipped with dry ice. For long-term storage, it is recommended to store the lentiviruses at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.

Biosafety



The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and after integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal and are not present in the lentivirus particle. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS Bioscience recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.

Notes

To generate a dominant negative TGF- β RII expressing stable cell line, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin (as predetermined from a killing curve, https://bpsbioscience.com/cell-line-faq), for antibiotic selection of transduced cells, followed by clonal selection.

Figures and Validation Data




Figure 2. Expression of dominant negative TGF-BRII in CHO cells transduced with Dominant Negative TGF-β Receptor Type II (TGF-BRII) Lentivirus.

Approximately 100,000 CHO-K1 cells were transduced with 1 x 10⁶ TU (100 μ l of 10⁷ TU/ml) of Dominant Negative TGF- β Receptor Type II (TGF- β RII) lentiviruses in the presence of 5 μ g/ml of Lenti-FuseTM Polybrene Viral Transduction Enhancer (BPS Bioscience #78939). 48 hours posttransduction, the cells were cultured with 5 μ g/ml of puromycin. The puromycin-resistant cell pool was stained with Human TGF-beta RII PE-conjugated Antibody (R&D Systems FAB2411P) and analyzed by flow cytometry. The y-axis represents the cell % and the x-axis indicates PE intensity.

Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com



2

Sequence

Human dominant negative TGF-βRII sequence (accession number NM_003242.6; amino acid 1-191)

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVC VAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISL LPPLGVAISVIIIFYCYRV

References

Ikushima H. and Miyazono K., 2010 *Nature Reviews Cancer* 10:415-424. Narayan V., *et al.*, 2022 *Nat Med* 28:724-34.

Troubleshooting Guide

Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For further questions, please email support@bpsbioscience.com.

Related Products

Products	Catalog #	Size
Firefly Luciferase-eGFP Lentivirus (G418 or Puromycin)	79980	500 μl x 2
Expression Negative Control Lentivirus (EF1A Promoter/ Puromycin)	82212-P	500 μl x 2
TGFBR2 CRISPR/Cas9 Lentivirus (Non Integrating)	78536	500 μl x 2
TGFBR2 CRISPR/Cas9 Lentivirus (Integrating)	78535	500 μl x 2
Lenti-Fuse™ Polybrene Viral Transduction Enhancer	78939	500 μl
TGF β -Responsive SBE Luciferase Reporter HEK293 Cell Line	60653	2 vials

Version 011624



3